Kimmtrak (Tebentafusp)

Kimmtrak (Tebentafusp) is filed as Bispecific T-Cell Engager. The sections below restate public label fields stored for this profile.

Class
Bispecific T-Cell Engager
Generic name
Tebentafusp
Route
INTRAVENOUS
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Injection: 100 mcg/0.5 mL clear, colorless to slightly yellowish solution in a single-dose vial Injection: 100 mcg/0.5 mL solution in a single-dose vial ( 3 ).
Manufacturer
Immunocore Commercial LLC
Boxed warning
Yes

Approved uses

1 INDICATIONS AND USAGE KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma ( 1 , 2.1 ).

How it works

12.1 Mechanism of Action Tebentafusp-tebn is a bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor CD3 T cell engager. The TCR arm binds to a gp100 peptide presented by human leukocyte antigen-A*02:01 (HLA-A*02:01) on the cell surface of uveal melanoma tumor cells. In vitro, tebentafusp-tebn bound to HLA-A*02:01-positive uveal melanoma cells and activated polyclonal T cells to release inflammatory cytokines and cytolytic proteins, which results in direct lysis of uveal melanoma tumor cells.

Boxed warning

WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated [(see Dosage and Administration (2.2) , see Warnings and Precautions (5.1) ] . WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated ( 2.2 , 5.1 ).

Contraindications

4 CONTRAINDICATIONS None. None ( 4 ).

Common side effects

F patients were cytokine release syndrome (10%); Rashes (4.5%); Pyrexia (2.4%); And hypotension (2%); One patient (0.4%); Of patients included fatigue (3.7%); Lipase increased (2.9%); Alanine aminotransferase increase (2%)

Adverse reactions

The following serious adverse reactions are discussed in greater detail in other sections of the label: Cytokine Release Syndrome [ see Boxed Warning , Warnings and Precautions (5.1) ] Skin Reactions [ see Warnings and Precautions (5.2) ] Elevated Liver Enzymes [ see Warnings and Precautions (5.3) ]

Dosage and administration

2 DOSAGE AND ADMINISTRATION Recommended dosage: 20 mcg intravenously on Day 1, 30 mcg intravenously on Day 8, 68 mcg intravenously on Day 15, and 68 mcg intravenously once every week thereafter ( 2.2 ). Dilute and administer by intravenous infusion over 15-20 minutes ( 2.2 , 2.4 ). See Full Prescribing Information for instructions on preparation and administration of the diluted solution for intravenous infusion ( 2.2 , 2.4 ). Dosage interruption or permanent discontinuation may be required based on individual safety and tolerability ( 2.3 ). 2.1 Patient Selection Select patients for treatment of unresectable or metastatic uveal melanoma with KIMMTRAK based on a positive HLA-A*02:01 genotyping test of a whole blood sample [see Clinical Studies (14) ] . Information on FDA-approved tests is available at http://www.fda.gov/companiondiagnostics . 2.2 Recommended Dosage The recommended dosage of KIMMTRAK administered intravenously is: 20 mcg on Day 1 30 mcg on Day 8 68 mcg on Day 15 68 mcg once every week thereafter Treat patients until unacceptable toxicity or disease progression occur. Administer the first three infusions of KIMMTRAK in an appropriate healthcare setting by intravenous infusion over 15-20 minutes. Monitor patients during the infusion and for at least 16 hours after the infusion is complete. If the patient does not experience Grade 2 or worse hypotension (requiring medical intervention) during or after the third infusion, administer subsequent doses in an appropriate ambulatory care setting, and monitor patients for a minimum of 30 minutes following each of these infusions [see Warnings and Precautions (5.1) ] . 2.3 Dosage Modifications for Adverse Reactions No dosage reduction for KIMMTRAK is recommended. Dosage modifications for KIMMTRAK for adverse reactions are summarized in Table 1 . Table 1: Dose Modifications for Adverse Reactions a Based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (NCI CTCAEv4.03). Adverse Reaction Severity KIMMTRAK Dosage Modifications Cytokine Release Syndrome (CRS) [see Warnings and Precautions (5.1) ] Moderate defined as temperature ≥ 38°C with Hypotension that responds to fluids (does not require vasopressors) or Hypoxia requiring low flow nasal canula (≤ 6 L/min) or blow-by oxygen If hypotension and hypoxia do not improve within 3 hours or CRS worsens, escalate care and manage according to next higher level of severity For moderate CRS that is persistent (lasting 2-3 hours) or recurrent, administer corticosteroid premedication (e.g. dexamethasone 4 mg or equivalent) at least 30 minutes prior to next dose Severe defined as temperature ≥ 38°C with Hemodynamic instability requiring a vasopressor (with or without vasopressin) or Worsening hypoxia or respiratory distress requiring high flow nasal canula (> 6 L/min oxygen) or face mask Withhold KIMMTRAK until CRS and sequelae have resolved Administer intravenous corticosteroid (e.g., 2 mg/kg/day methylprednisolone or equivalent) Resume KIMMTRAK at same dose level (i.e., do not escalate if severe CRS occurred during initial dose escalation; resume escalation once dosage is tolerated) For severe CRS, administer corticosteroid premedication (e.g. dexamethasone 4 mg or equivalent) at least 30 minutes prior to next dose Life threatening defined as temperature ≥ 38°C with Hemodynamic instability requiring multiple vasopressors (excluding vasopressin) Worsening hypoxia or respiratory distress despite oxygen administration requiring positive pressure Permanently discontinue KIMMTRAK Administer intravenous corticosteroid (e.g., 2 mg/kg/day methylprednisolone or equivalent) Skin Reactions [see Warnings and Precautions (5.2) ] Grade 2 or 3 a Withhold KIMMTRAK until ≤ Grade 1 or baseline Resume KIMMTRAK at same dose level (i.e., do not escalate if Grade 3 skin reactions occurred during initial dose escalation; resume escalation once dosage is tolerated) For persistent reactions not responding to oral steroids, consider intravenous corticosteroid (e.g., 2 mg/kg/day methylprednisolone or equivalent) Grade 4 a Permanently discontinue KIMMTRAK Administer intravenous corticosteroid (e.g., 2 mg/kg/day methylprednisolone or equivalent) Elevated Liver Enzymes [see Warnings and Precautions (5.3) ] Grade 3 or 4 a Withhold KIMMTRAK until ≤ Grade 1 or baseline. Resume KIMMTRAK at same dose level if the elevated liver enzymes occur in the setting of Grade 3 CRS; resume escalation if next administration is tolerated. If the elevated liver enzymes occur outside the setting of Grade 3 CRS resume escalation if the current dose is less than 68 mcg, or resume at same dose level if dose escalation has completed Administer intravenous corticosteroids if no improvement within 24 hours Other Adverse Reactions [see Adverse Reactions (6.1) ] Grade 3 a Withhold KIMMTRAK until ≤ Grade 1 or baseline Resume KIMMTRAK at same dose level (i.e., do not escalate if other Grade 3 adverse reaction occurred during initial dose escalation; resume escalation once dosage is tolerated) Grade 4 a Permanently discontinue KIMMTRAK 2.4 Preparation and Administration Preparation A 2-step dilution process is required for preparation of the final KIMMTRAK dose for infusion. Use aseptic technique for dilution and preparation of intravenous infusion solutions. Visually inspect parenteral drug products and infusion bags for particulate matter and discoloration prior to administration, whenever solution and container permit. Step 1: Preparation of the Infusion Bag To prevent adsorption of tebentafusp-tebn to the infusion bag and other components of the drug delivery system, prepare an Albumin (Human) in 0.9% Sodium Chloride Injection, USP solution as follows: Using a 1 mL syringe with graduations of 2 decimal places and a sterile needle, withdraw the calculated volume of Albumin (Human) into the syringe (see Table 2 below) and add to the 100 mL 0.9% Sodium Chloride Injection, USP bag constructed of polyolefins (PO) [such as polyethylene (PE) and polypropylene (PP)] or polyvinyl chloride (PVC) to make a final Albumin (Human) concentration of 250 mcg/mL. Table 2: Examples of Albumin (Human) Concentration and Volumes *Albumin (Human); use concentration as per local availability. Examples include but are not restricted to the following strengths: 5%, 20%, or 25%. Albumin (Human) concentration* Albumin (Human) volume for addition to a 100 mL 0.9% Sodium Chloride Injection, USP Infusion Bag to prepare a concentration of 250 mcg/mL Albumin (Human) in 0.9% Sodium Chloride Injection, USP 5% (50 g/L) 0.5 mL 20% (200 g/L) 0.13 mL 25% (250 g/L) 0.1 mL Gently homogenize the prepared solution by completing the following steps: Invert the infusion bag so that the bag is upside down with the entry port positioned on top. Then tap the side of the port tubing to ensure that any residual solution is released into the bulk solution. Mix the prepared solution by gently rotating the bag lengthwise 360 degrees from the inverted position at least 5 times. Do not shake the infusion bag. Repeat (i) and (ii) an additional three times. Step 2- Preparation of KIMMTRAK Solution for Infusion Do not shake the KIMMTRAK vial. Using a 1 mL syringe with graduations of 2 decimal places and a sterile needle, withdraw the required volume of KIMMTRAK 100 mcg/ 0.5 mL as per the dose required (shown in Table 3 below) and add to the prepared 100 mL infusion bag containing 0.9% Sodium Chloride Injection, USP plus Albumin (Human). Discard the single-dose vial containing the unused portion of KIMMTRAK in accordance with local requirements. Do not prepare more than one dose from the vial. Table 3: KIMMTRAK Volumes Required for Addition to the Infusion Bag Day of treatment Dose (mcg) of KIMMTRAK Volume (mL) of KIMMTRAK Day 1 20 0.1 Day 8 30 0.15 Day 15 and weekly thereafter 68 0.34 Mix the infusion bag by following the same procedure outlined in Step 1b. Administration Immediately administer the diluted solution via…

Common questions

What is Kimmtrak approved to treat?

According to its FDA label, Kimmtrak (Tebentafusp) is approved for: 1 INDICATIONS AND USAGE KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Kimmtrak?

Kimmtrak (Tebentafusp) belongs to the Bispecific T-Cell Engager class of medications.

What form does Kimmtrak come in?

The FDA label lists Kimmtrak (Tebentafusp) as: 3 DOSAGE FORMS AND STRENGTHS Injection: 100 mcg/0.5 mL clear, colorless to slightly yellowish solution in a single-dose vial Injection: 100 mcg/0.5 mL solution in a single-dose vial ( 3 ).; intravenous route. Available strengths and packaging vary by manufacturer.

Does Kimmtrak have a Boxed Warning?

Yes. The FDA label for Kimmtrak (Tebentafusp) carries a Boxed Warning. Excerpt: "WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and the…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

How much does Kimmtrak cost?

Public CMS NADAC pricing for Kimmtrak (Tebentafusp) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Kimmtrak currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Kimmtrak (Tebentafusp) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Kimmtrak approved by the FDA?

The FDA record lists the approval date for Kimmtrak (Tebentafusp) as 2022-01-25.

Who makes Kimmtrak?

The FDA label lists Immunocore Commercial LLC as a labeler/manufacturer of Kimmtrak (Tebentafusp). Multiple firms may market generics of the same molecule.

How should Kimmtrak be stored?

The FDA label states: "How Supplied Each KIMMTRAK (tebentafusp-tebn) injection carton (NDC 80446-401-01) contains: One single-dose vial containing 100 mcg of tebentafusp-tebn in 0.5 mL of sterile, preservative-free, clear, colorless or slightl…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…